Press

Press kit.

The marks, the facts, and the sentence we would like quoted. Biolyz has been covered by The New York Times, kicker and Sportico.

Read the coverage →Download the press kit (ZIP, 13 MB)

Sample.
Signal.
Decision.

The marks

Two lockups, one colour each.

Both marks are single-colour and inherit whatever they sit on. On the off-white ground use ink; on the blue-black ground use off-white. Do not recolour them to the brand blue, and do not add a shadow.

SignetFavicons, app icons, anywhere under 40 px.Download SVG

Horizontal lockupThe default. Headers, documents, partner walls.Download SVG

On the inverted groundSame file. It inherits the colour of whatever it sits in.

Boilerplate

The facts, checkable.

What it is: The first saliva based, non-invasive biomarker platform for elite teams.
Panel: 60+ biomarkers from a single swab, 48 h turnaround, zero needles.
Method: LC–MS/MS on 1 ml of saliva, targeted quantification.
Scale: 11,000+ active sessions · 25,000+ samples in the last 12 months · 2.5M+ analysed biomarkers.
Named clubs: Bayer 04 Leverkusen, Borussia Dortmund.
Founded: 2021, by Marlon Millard, who is chief executive.
Entity: BIOLYZ FlexCo, Technopark 1/D, 3430 Tulln an der Donau, Austria.
Certification: ISO 27001.
Taglines: “Know more. Hurt less.” · “Sample. Signal. Decision.”